Back

Soluble urokinase plasminogen activator surface receptor as a prognostic biomarker in heart failure

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - epidemiology, prognosis, outcome 7 Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Amra Jujic

Lund University, Malmo (Sweden)

7 More presentations in this session

Presentation thumbnail
Identifying predictors of risk stratification in hospitalized heart failure patients
Doctor J. Cizek (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Incidence and predictors of worsening heart failure.
Doctor J. Bonilla Palomas (Ubeda, ES)
Abstract Slides Video
Presentation thumbnail
Incidence and predictors of mortality and hospital readmissions in a contemporary cohort of patients with heart failure.
Doctor J. Bonilla Palomas (Ubeda, ES)
Abstract Slides Video
Presentation thumbnail
Comparison of clinical characteristics and survival between ischemic and non-ischemic patients heart failure patients with reduced ejection fraction: an observational study
Doctor M. Kose (Izmir, TR)
Abstract Slides Video
Presentation thumbnail
Baseline characteristics and one year outcome of patients in CABG PREFERS (coronary artery bypass graft preserved and reduced ejection fraction epidemiological regional study)
Doctor U. Lofstrom (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - epidemiology, prognosis, outcome 7

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Soluble urokinase-type plasminogen activator surface receptor is associated with kidney disease in heart failure patients
thumbnail
Congress Presentation
The cardioprotective potential of soluble urokinase Plasminogen Activator Receptor (suPAR) in myocardial ischemia.
thumbnail
Congress Presentation
Association of preoperative NT-proBNP with 30-day and five-year mortality after cardiac surgery

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources